ライフサイエンスコーパス: immunoglobulin

1 neuropathy (CIDP) need long-term intravenous immunoglobulin.

2 r an immunochromatographic assay of specific immunoglobulins.

3 apolipoproteins, complement components, and immunoglobulins.

4 d levels of soluble BAFF, B lymphocytes, and immunoglobulins.

5 rmation for profiling of N-linked glycans on immunoglobulins.

6 tervals, PPH (6x), and high-dose intravenous immunoglobulin (1.5 g/kg).

7 Large quantities of immunoglobulin A (IgA) are constitutively secreted by in

8 in the HIV-1+ infants, whereas antirotavirus immunoglobulin A (IgA) levels were not.

9 Secretory immunoglobulin A (SIgA) enhances host-microbiota symbios

10 sies in children with symptoms and levels of immunoglobulin A against tissue-transglutaminase (TGA-Ig

11 Elevated serum immunoglobulin A and immunoglobulin G titers were associ

12 ere seronegative at baseline, anti-rotavirus immunoglobulin A seroconversion rates after 3 vaccine do

13 zation and induction of immunoglobulin G and immunoglobulin A to all antigens tested, while causing n

14 um total free light chain, immunoglobulin G, immunoglobulin A, and immunoglobulin M were measured on

15 The genetic component of Immunoglobulin-A (IgA) vasculitis is still far to be elu

16 ographic assay for the detection of specific immunoglobulins against a target antigen (antibodies) in

17 jection of heat-aggregated human intravenous immunoglobulin and active systemic anaphylaxis after imm

18 ed C1 levels were best correlated with local immunoglobulin and C5a levels.

19 Intravenous immunoglobulin and corticosteroids were effective in thr

20 , members of the tyrosine kinase family with immunoglobulin and EGF homology domains, are receptor ty

21 tain giant polypeptides composed of multiple immunoglobulin and fibronectin domains and one or two pr

22 on glass coverslips coated with intravenous immunoglobulin and inactive complement component 3b.

23 T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory

24 racterized by increased expression of T-cell immunoglobulin and mucin domain 3, which down-regulates

25 human syndecan-1 (SDC-1), SDC-2, and T cell immunoglobulin and mucin domain-containing protein 1 (TI

26 lymphocyte-activation gene 3 (LAG-3), T cell immunoglobulin and mucin-3 (TIM-3), and/or programmed ce

27 The high levels of immunoglobulin and plasma cell transcripts is consistent

28 may indicate only some interactions between immunoglobulins and ABTs clear pneumococcal colonization

29 as lesser allergic phenotypes, reduced serum immunoglobulins and allergic mediators, lower mast cells

30 relationship between high free light chain, immunoglobulins and hospital mortality.

31 antation, there is a gradual increase of all immunoglobulins and IgG subclasses, but values were alwa

32 levels of A. actinomycetemcomitans-specific immunoglobulins and increasing age.

33 nd the first to study two administrations of immunoglobulins and two doses, showed that both doses of

34 ral nerve involvement, an intact circulating immunoglobulin, and lower circulating dFLC.

35 nticoagulation, corticosteroids, intravenous immunoglobulin, and plasma exchange are the most commonl

36 utate viral pathogens and somatically mutate immunoglobulins, and contribute to the diversification a

37 Immunoglobulins are the effector molecules of the adapti

38 d using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagn

39 he mechanism of conversion of broad-spectrum immunoglobulin-binding proteins, such as HTB1, into targ

40 ve with GABA-enhancing drugs and intravenous immunoglobulin, but some respond poorly and remain disab

41 ted for rotavirus and sera for antirotavirus immunoglobulins by enzyme immunoassays.

42 CNTN4 consists of six immunoglobulin C2 type (IgC2) domains and four fibronect

43 tential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications

44 d decrease in NHEJ is insufficient to impact immunoglobulin class switching in DEK knockout mice.

45 ivo capacity to induce B cell maturation and immunoglobulin class switching than cells from HIV progr

46 otype in B cells and supports a controllable immunoglobulin class-switching reaction.

47 versial, with detection prevalence rates and immunoglobulin classes varying considerably between stud

48 rmal immune cell repertoire, unchanged serum immunoglobulin concentrations and an intact immune respo

49 The reduced immunoglobulin concentrations in the interstitial tissue

50 ICU admission day free light chain and immunoglobulin concentrations were significantly correla

51 ding transcripts originating upstream of the immunoglobulin constant region (I transcripts) are requi

52 Light chains kappa and lambda are immunoglobulin constituents but also circulate independe

53 homa, activating RAS mutations may propagate immunoglobulin-crippled tumour cells, which usually repr

54 including glucocorticosteroids, intravenous immunoglobulins, cyclosporine, plasmapheresis, thalidomi

55 Immunoglobulin-cytokine fusion molecules have been shown

56 ad lymphocyte-maturation defects that caused immunoglobulin deficiency and intestinal inflammation.

57 globulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been inv

58 y by C3 accumulation with absent, or scanty, immunoglobulin deposits.

59 ated circulating CD4(+) T cells specific for immunoglobulin-derived neoantigens and found these cells

60 rystal structure of TIGIT bound to the first immunoglobulin domain of nectin-2 indicated that the rec

61 Here, we show that TIGIT bound to the immunoglobulin domain of nectin-2 that is most distal fr

62 ide analysis of members of a small family of immunoglobulin domain proteins, we found that OIG-8, a p

63 ound to IL-23 exclusively via its N-terminal immunoglobulin domain.

64 ave similar architectures, with the variable immunoglobulin domains of the heavy and light chain each

65 IV immunoglobulins were infused (IV immunoglobulin) during 15 episodes (25.4%).

66 The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the fir

67 everal extracellular cues, including antigen-immunoglobulin E (IgE) complexes, bacteria, viruses, cyt

68 gnificant reduction in STH prevalence, total immunoglobulin E (IgE), and eosinophil count.

69 y fever, allergic sensitization, serum total immunoglobulin E (IgE), forced expiratory volume in one-

70 We identified unique signatures for AD (Immunoglobulin E (IgE), thymus- and activation-regulated

71 an emphasis on novel FcepsilonRI regulators, immunoglobulin E (IgE)-independent pathways [e.g., Mas-r

72 sthma, atopic dermatitis, and elevated total immunoglobulin E (IgE).

73 kin tests and measurement of serum levels of immunoglobulin E do not accurately identify foods for el

74 nificantly correlated with decrease in total immunoglobulin E level (rho = 0.47; P = .04).

75 Omalizumab, an anti-immunoglobulin E monoclonal antibody, has transformed th

76 efit from targeted anti-interleukin and anti-immunoglobulin E therapies, and in monitoring subsequent

77 sensitization by specific serum antibodies (immunoglobulin E) against aero-allergens.

78 Cross-linking of immunoglobulin E-bound FcepsilonRI triggers multiple cel

79 rmalized circulating levels of cytokines and immunoglobulin E.

80 rrelated with levels of C5a (P < .01), local immunoglobulins (especially IgM, P < .0001), and anti-do

81 s are mediated by the complement receptor of immunoglobulin family (CRIg).

82 thers and the routine use of cytomegalovirus immunoglobulin for prophylaxis or treatment of infected

83 at daily injections of osteoprotegerin (OPG)-immunoglobulin fragment complex (OPG-Fc) completely rest

84 c IgE, IgG, IgG4, and IgM levels, as well as immunoglobulin free light chains, were measured in both

85 Immunoprecipitated sputum immunoglobulins from patients with increased autoantibod

86 lyte binding interactions between anti-human immunoglobulin G (anti-hIgG) and human immunoglobulin G

87 Polyclonal anti-immunoglobulin G (anti-IgG) secondary antibodies are ess

88 ell-based assays for MOG-IgG and aquaporin-4 immunoglobulin G (AQP4-IgG).

89 human immunoglobulin G (anti-hIgG) and human immunoglobulin G (hIgG).

90 n the presence of reactive, non-neutralizing immunoglobulin G (IgG) (RNNIg) is the greatest risk fact

91 protective role for both Chlamydia-specific immunoglobulin G (IgG) and polymorphonuclear neutrophils

92 Dengue immunoglobulin G (IgG) antibodies were measured at basel

93 c opsonophagocytic activity (OPA) titers and immunoglobulin G (IgG) concentrations were determined.

94 ZIKV-NS1 immunoglobulin M (IgM) and immunoglobulin G (IgG) ELISAs combined can detect ZIKV i

95 Total immunoglobulin G (IgG) from individuals residing in mala

96 N-linked glycans on immunoglobulin G (IgG) have been associated with pathoge

97 amma receptors (FcgammaRs), the Fc domain of immunoglobulin G (IgG) mediates a wide spectrum of immun

98 ariate genome-wide association studies of 23 immunoglobulin G (IgG) N-glycosylation phenotypes.

99 Heat maps for human immunoglobulin G (IgG) responses for each village and su

100 Serum immunoglobulin G (IgG) titers to 28 pneumococcal protein

101 ree-dimensional (3D) ordered arrays of human immunoglobulin G (IgG) were fabricated using well-define

102 ased class switched memory B cells and serum immunoglobulin G (IgG).

103 n-protein interfaces in the GB1 complex with immunoglobulin G (IgG).

104 d interface for the attachment of monoclonal immunoglobulin G (IgGNS1) and to favor specific detectio

105 inked dimer fused to the Fc portion of mouse immunoglobulin G (sP-selectin-Fc).

106 There was an unexpected persistence of immunoglobulin G almost until weaning, potentially indic

107 nasopharyngeal colonization and induction of immunoglobulin G and immunoglobulin A to all antigens te

108 yme-linked immunosorbent assay for anti-HCMV immunoglobulin G and immunoglobulin M and for cIL-10 and

109 nes, correlated directly with B. burgdorferi immunoglobulin G antibodies (P </= .02), suggesting a be

110 our studies on posttransplant production of immunoglobulin G antibodies targeting cell surface antig

111 ntrations and neutralizing activity of serum immunoglobulin G antibodies to the RSV prefusion (pre-F)

112 itis C therapy in patients carrying anti-HEV immunoglobulin G antibodies, raising 2 major questions:

113 Higher immunoglobulin G antibody levels among those seropositiv

114 On day 29, 92.9% of vaccinees had an anti-F immunoglobulin G antibody seroresponse.

115 Eight patients with endocarditis had phase I immunoglobulin G antibody titers >800 but did not meet t

116 Only immunoglobulin G avidity index was higher in nontransmit

117 globulin M-positive and low or moderate HCMV immunoglobulin G avidity.

118 The primary endpoint was serotype-specific immunoglobulin G concentrations values (geometric mean c

119 oconversion, defined as a 4-fold increase in immunoglobulin G directed against Cryptosporidium gp15 a

120 Among 34 patients (91.9%) with monoclonal immunoglobulin G gammopathy, 20 (58.8%) had kappa light

121 Each immunized mouse had substantial immunoglobulin G targeting the challenge strains, indica

122 Elevated serum immunoglobulin A and immunoglobulin G titers were associated with partial pro

123 croarray antibody capture assay for anti-HDV immunoglobulin G wherein recombinant HDV delta antigen i

124 glucose, ascorbic acid human serum protein, immunoglobulin G, and immunoglobulin M), and demonstrate

125 Serum total free light chain, immunoglobulin G, immunoglobulin A, and immunoglobulin M

126 model protein in human serum, that is, human immunoglobulin G, with the aim to demonstrate a virtuall

127 Immunoglobulin G1 (IgG1), a subclass of human serum anti

128 ELISA) was used to investigate serum anti-CT immunoglobulin G1 (IgG1; long-lived response) and immuno

129 lence of myelin oligodendrocyte glycoprotein immunoglobulin G1 (MOG-IgG) and associated clinical feat

130 exploiting the stable architecture of human immunoglobulin G1 We used iterative experimental validat

131 iotherapeutic filgrastim, and the Fc part of immunoglobulin G1.

132 oglobulin G1 (IgG1; long-lived response) and immunoglobulin G3 (IgG3; short-lived response indicating

133 extended version of our previously published ImmunoGlobulin Galaxy (IGGalaxy) virtual machine that wa

134 with a distinct strand bias, to enlarge the immunoglobulin gene mutation spectrum from G-C to A-T ba

135 During somatic hypermutation (SHM) of immunoglobulin genes, uracils introduced by activation-i

136 We also tested the ability to generate immunoglobulin germline and circle transcripts and to up

137 dentify a novel susceptibility signal in the immunoglobulin heavy chain (IGH) locus centring on a hap

138 We identify the immunoglobulin heavy chain (IGH) locus to be associated

139 inding protein homologous protein (chop) and immunoglobulin heavy chain binding protein (bip) levels.

140 and antisense strand DNA mutagenesis at the immunoglobulin heavy chain locus and some other regions

141 Multivariate modeling revealed immunoglobulin heavy chain variable gene (IGHV) mutation

142 , we performed high-throughput sequencing of immunoglobulin heavy chain VDJ rearrangements of naive,

143 Skewing of the immunoglobulin heavy variable (IGHV) gene repertoire was

144 s were exclusively derived from the lymphoma immunoglobulin heavy- or light-chain variable regions.

145 rs, interleukin-10, chemokine receptors, and immunoglobulin heavy-chain isotypes, was measured.

146 l of EV-D68 infection: (1) human intravenous immunoglobulin (hIVIG), (2) fluoxetine, and (3) dexameth

147 s with nasal polyps is associated with local immunoglobulin hyperproduction and the presence of IgE a

148 protein-protein interfaces of two different immunoglobulin (Ig) constant domain pairs are exchanged

149 Two immunoglobulin (Ig) diversification mechanisms collabora

150 cterized transmembrane protein with a single immunoglobulin (Ig) domain, instructs the distinct, neur

151 k binds to the leucine-rich repeat (LRR) and immunoglobulin (Ig) domains of Gpr124, and weakening thi

152 predicted peak of pollen) to determine serum immunoglobulin (Ig) E concentrations and Treg percentage

153 , or elevated allergen-specific serum/plasma immunoglobulin (Ig) E levels later in life.

154 Results were correlated with immunoglobulin (Ig) G responses.

155 For groups 1 and 2, plasma immunoglobulin (Ig) G, IgA, and neutralizing antibody re

156 Antibodies (Abs) produced by immunoglobulin (IG) genes are the most diverse proteins

157 inase (AID) is a mutator enzyme that targets immunoglobulin (Ig) genes to initiate antibody somatic h

158 was largely mediated by germline encoded and immunoglobulin (Ig) heavy-chain complementarity determin

159 The germline immunoglobulin (Ig) variable heavy chain 4-34 (VH4-34) g

160 iver disease often manifests systemically as immunoglobulin (Ig)-related syndromes due to aberrant B-

161 tromal lymphopoietin, IL-5 and IL-13), serum immunoglobulin (Ig)E and airway hyper-responsiveness (AH

162 omic DNA, and infection elicited significant immunoglobulin (Ig)G and IgM antibody responses, indicat

163 tion, there is a significant decrease of all immunoglobulins, IgG subclasses and pneumococcal polysac

164 Consistent with this observation, the immunoglobulin (Igh) gene deamination as measured by ura

165 e, phenylacetylglycine, alanine) and mucosal immunoglobulin (IgM) and cytokine (IL-10, IL-4) producti

166 to maintain homeostasis is the secretion of immunoglobulins (Igs) across epithelial barriers, which

167 tic epitopes exposed in the hinge regions of immunoglobulins (Igs) and do not bind to the intact Ig c

168 n-1 receptor 8 (IL-1R8, also known as single immunoglobulin IL-1R-related receptor, SIGIRR, or TIR8)

169 n the treatment group, or an isotype-matched immunoglobulin in the control group.

170 As encoding rearranged heavy and light chain immunoglobulins in B cells.

171 were observed, with recovery of B cells and immunoglobulins in some patients.

172 volumes were tested for association with the immunoglobulin indices and the frequencies of immune cel

173 usions (IUPT), as well as weekly maternal IV immunoglobulin infusion (IVIG), with or without addition

174 combined with plasmapheresis and intravenous immunoglobulins is an option for patients with AMR.

175 ed AHR, suggesting that transfer of maternal immunoglobulins is not required.

176 feration and guide their differentiation and immunoglobulin isotype switching by delivering contact-d

177 Intravenous immunoglobulin (IVIG) are purified IgG preparations made

178 Intravenous immunoglobulin (IVIG) is a FDA-approved drug containing

179 Intravenous immunoglobulin (IVIG) is sometimes administered for pres

180 Intravenous immunoglobulin (IVIG) is the treatment of choice in Kawa

181 all trials suggest that low-dose intravenous immunoglobulin (IVIg) may improve the symptoms of comple

182 To determine the effect of intravenous immunoglobulin (IVIG) on brain atrophy and cognitive fun

183 Intravenous immunoglobulin (IVIG), a pooled normal IgG formulation p

184 of GBS in patients treated with intravenous immunoglobulin (IVIG).

185 ma donors, which is reflected in intravenous immunoglobulins (IVIGs).

186 of recombination signal-binding protein for immunoglobulin Jkappa region (RBPJkappa), a downstream e

187 and recombination signal binding protein for immunoglobulin kappa J region (RBPjkappa), key modulator

188 ociated lymphoid tissue (MALT) lymphoma with immunoglobulin kappa monotype.

189 Since 2010, immunoglobulin knockin (KI) technology, involving insert

190 y inflammation, TH2 cytokine production, and immunoglobulin levels and a modest decrease in the phago

191 Immunoglobulin levels and T-cell repertoire normalized,

192 Immunoglobulin levels remain decreased several years aft

193 tion markers, and proliferation and secreted immunoglobulin levels were analyzed by using flow cytome

194 Low immunoglobulin levels were commonplace (45.5%) at ICU ad

195 Among patients with immunoglobulin light chain (AL) amyloidosis, there is li

196 In light of major advances in immunoglobulin light chain (AL) amyloidosis, we evaluate

197 xazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis.

198 The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achi

199 BCR knock-in mice lacking self-Thy-1 ligand, immunoglobulin light chain editing occurred, generating

200 n both AL and multiple myeloma (MM), soluble immunoglobulin light chains (LC) are produced by clonal

201 arge membrane pores and high permeability to immunoglobulin light chains) or a conventional high-flux

202 al lymphoplasmacytic malignancies, including immunoglobulin light-chain amyloidosis, multiple myeloma

203 tional dynamics of a pathogenic kappa4 human immunoglobulin light-chain variable domain, SMA, associa

204 izing and destabilizing mutations is key for immunoglobulin light-chains populating unfolded intermed

205 for NK cell inhibition via inhibitory killer immunoglobulin-like (KIR) receptors and interrupts their

206 riant of human peroxidasin 1 comprising four immunoglobulin-like domains and the catalytically active

207 e complex shows how AlkC uses unique HLR and immunoglobulin-like domains to induce a sharp kink in th

208 antigenic motifs in a single-domain chimeric immunoglobulin-like fold generated a vaccine that greatl

209 CD22 is a sialic acid-binding immunoglobulin-like lectin (Siglec) that is highly expre

210 Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a cell-surface

211 cell alloreactivity mediated by killer cell immunoglobulin-like receptor (KIR)-HLA interactions may

212 receptor B1 (LILRB1) or leucocyte-associated immunoglobulin-like receptor 1 (LAIR1).

213 NKp44 expression, and remarkable killer cell immunoglobulin-like receptor acquisition.

214 a subset of RIFINs binds to either leucocyte immunoglobulin-like receptor B1 (LILRB1) or leucocyte-as

215 ucts (RAGE) is an ubiquitous, transmembrane, immunoglobulin-like receptor that exists in multiple iso

216 e frequently expressed educating killer cell immunoglobulin-like receptors compared with NK cells in

217 immune-cell-specific genes, including novel immunoglobulin-like receptors, and neofunctionalization

218 eater degree with the gB receptor the paired immunoglobulin-like type 2 receptor alpha (PILRalpha) th

219 re composed of alphabeta subunits displaying immunoglobulin-like variable domains that recognize pept

220 We report that certain Sialic-acid-binding immunoglobulin-like-lectins (siglecs) are expressed in h

221 tion via Pfs25 virus-like particles in human immunoglobulin loci transgenic mice.

222 genic translocations involving c-Myc and the immunoglobulin locus.

223 formed in switch regions on the heavy-chain immunoglobulin locus.

224 terize the nanoscale spatial organization of immunoglobulin M (IgM) and IgG BCRs on the surfaces of r

225 GC-dependent immune responses, reduces total immunoglobulin M (IgM) and IgG levels, and leads to incr

226 ZIKV-NS1 immunoglobulin M (IgM) and immunoglobulin G (IgG) ELISAs

227 ptor for the crystallizable fragment (Fc) of immunoglobulin M (IgM) can function as a cell-surface re

228 An immunoglobulin M (IgM) kappa paraprotein was detected in

229 % CI: 0.7-4.7%) for Epstein-Barr virus (EBV) immunoglobulin M (IgM) positivity, 94.7% (95% CI: 90.7-9

230 infections and rule out misleading positive immunoglobulin M (IgM) results in areas with various lev

231 Mumps immunoglobulin M (IgM) testing was negative and reverse-

232 globulinemia (MC), a monoclonal expansion of immunoglobulin M (IgM)(+) autoreactive B cells, and also

233 t expression of the secretory heavy chain of immunoglobulin M (micros), is well-tolerated in HeLa cel

234 ent assay for anti-HCMV immunoglobulin G and immunoglobulin M and for cIL-10 and vIL-10 levels using

235 (-) T cells, and decreases in elevated serum immunoglobulin M and inflammatory markers including inte

236 eroprevalence of ZIKV was 6.2% based on ZIKV immunoglobulin M and negative for dengue reactivity.

237 h nonsense CXCR4 mutations have higher serum immunoglobulin M levels and incidence of symptomatic hyp

238 w lower bone marrow disease burden and serum immunoglobulin M levels but show an increased risk of de

239 ain, immunoglobulin G, immunoglobulin A, and immunoglobulin M were measured on ICU days 1, 3, and 7.

240 infection (viral nonstructural protein 1 and immunoglobulin M) has greatly simplified laboratory-base

241 d human serum protein, immunoglobulin G, and immunoglobulin M), and demonstrated a high correlation w

242 based on seroconversion for HCMV and/or HCMV immunoglobulin M-positive and low or moderate HCMV immun

243 of the CSF samples tested positive for ZIKV immunoglobulin M.

244 athy (C3G) emphasizes the role of monoclonal immunoglobulin (MIg) in the occurrence of renal disease

245 a monoclonal band, which was confirmed to be immunoglobulin Mlambda at immunofixation.

246 to clone and sequence heavy and light chain immunoglobulin mRNAs.

247 ression of tumorigenicity-2 (ST2) and T-cell immunoglobulin mucin-3 (TIM3) at day 28 correlated with

248 tor accessory protein (IL1RAP), CD99, T-cell immunoglobulin mucin-3, and CD123 have begun to differen

249 ed of steroids (n = 61/74; 82%), intravenous immunoglobulins (n = 71/74; 96%), and plasmapheresis (n

250 f this strategy to human lymphoma implicates immunoglobulin neoantigens as targets for lymphoma immun

251 osuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without

252 nths before screening, or use of intravenous immunoglobulin or plasma exchange within 4 weeks before

253 Human immunoglobulin preparations for intravenous or subcutane

254 Immunoglobulin production and cellular analysis were per

255 rogeneous syndrome characterized by impaired immunoglobulin production and usually presents with a no

256 L-2 receptor alpha chain levels and in vitro immunoglobulin production by cultured B cells were quant

257 erresponsiveness (AHR), airway inflammation, immunoglobulin production, TH2-associated cytokine synth

258 iP (glucose-regulated protein 78 kDa/binding immunoglobulin protein) modulates protein folding in rep

259 In addition, immunoglobulin receptor (FcepsilonRI, FcgammaRII) expres

260 arriers, which is achieved via the polymeric immunoglobulin receptor (pIgR).

261 IgA into the intestinal lumen, the polymeric immunoglobulin receptor, was also dependent on IL-17RA s

262 CD28 and CTLA-4 are members of a family of immunoglobulin-related receptors that are responsible fo

263 A major TR binding site in the immunoglobulin repeat 21 (Ig21) of filamin is masked by

264 ad persistent medical issues, mainly ongoing immunoglobulin replacement (14; 45%), cutaneous viral wa

265 Given that immunoglobulin replacement therapy can effectively preve

266 mmune reconstitution, and discontinuation of immunoglobulin replacement therapy were recorded.

267 mphocyte/myeloid chimerism and are free from immunoglobulin replacement therapy.

268 ophylactic antimicrobials, and 5 have ceased immunoglobulin replacement.

269 rder to diminish the requirements for rabies immunoglobulin (RIG) and multiple vaccinations for effec

270 Subcutaneous immunoglobulin (SCIg) is an alternative option for immun

271 tective antibody levels for years due to the immunoglobulin-secreting activity of long-lived plasma c

272 ey inhibited B-cell differentiation, impeded immunoglobulin secretions, and expanded Foxp3(+)CXCR5(+)

273 and IgD(-)CD27(+) memory cells and triggered immunoglobulin secretions.

274 ononuclear cells (PBMCs), and used available immunoglobulin sequences and 5' and 3' RACE to clone and

275 oles in gene expression and recombination at immunoglobulin sites, their persistence is thought to in

276 ell-surface and secreted proteins containing immunoglobulin superfamily (IgSF) domains discovered a n

277 Immunoglobulin superfamily adhesion molecules are among

278 ession screens and proteomics, we identified immunoglobulin superfamily member 21 (IgSF21) as a neure

279 Programmed death one homolog (PD-1H) is an immunoglobulin superfamily molecule and primarily acts a

280 Homophilic binding of immunoglobulin superfamily molecules such as the Aplysia

281 Junctional adhesion molecule C (JAM-C) is an immunoglobulin superfamily protein expressed in epitheli

282 Expanding to the immunoglobulin superfamily reveals that a subset of non-

283 discontinue immunosuppression and exogenous immunoglobulin support, with improvement in vasculitic d

284 V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) i

285 ontaining substrates mimicking the mammalian immunoglobulin switch regions are particularly good AID

286 esults with standard MRD monitoring based on immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangeme

287 sent antigens to CD4 T cells and produce IgE immunoglobulins that arm effector cells; however, mouse

288 We confirmed that human plasma contains immunoglobulins that can neutralize ILY, MsgA, and NanA

289 In response to the 2014 outbreak, an ovine immunoglobulin therapy was developed, termed EBOTAb.

290 an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006.

291 the anti-inflammatory activity of human i.v. immunoglobulin therapy.

292 The ability of sputum immunoglobulins to induce eosinophil degranulation in vi

293 ith IgA, IgG or IgM levels or with composite immunoglobulin traits, accounted for by 32 loci.

294 r probable CIDP who responded to intravenous immunoglobulin treatment were eligible.

295 IV immunoglobulin use was not associated with improved surv

296 ones of memory B cells that express the same immunoglobulin VH3-23/VK1-5 genes.

297 immunotherapy with steroids and intravenous immunoglobulins vs. late immunotherapy), and a low white

298 st-HCT median CD4 counts and freedom from IV immunoglobulin were improved after the use of preparativ

299 Grass pollen-specific immunoglobulins were analysed before and after treatment

300 IV immunoglobulins were infused (IV immunoglobulin) during

301 Antivenoms are mammalian immunoglobulins with the ability to neutralize snake ven